 |
|
Study finds no relationship between PCR rate and race in women with breast cancer
October 12, 2009Blacks, whites, Hispanics who achieve milestone all have better outcomes
SAN FRANCISCO - Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
The study, presented in a poster discussion session at the 2009 Breast Cancer Symposium in San Francisco, is the largest in a homogenous group of breast cancer patients evaluating pathological complete response (pCR) according to race. Only one other study, also conducted at M. D. Anderson but limited to triple negative breast cancer patients (estrogen and progesterone receptor negative, HER2 negative), has analyzed the relationship between the two.
"Our findings confirm pathological complete response is a strong prognostic indicator and a surrogate for good survival, despite a patient's race, and that it's vital we continue to strive towards achieving this milestone for all women with breast cancer," said Mariana Chavez Mac Gregor, M.D., a medical oncology fellow at M. D. Anderson. "The study also mandates that we continue to research the differences across races in breast cancer."
Racial disparities in breast cancer are known: the American Cancer Society (ACS) estimates that 19,540 blacks and 14,200 Hispanics will be diagnosed with the disease in 2009. While the overall incidence rate is 10 percent lower in blacks than whites, in 2001-2005, they had a 37 percent higher death rate. ACS also reports that overall breast cancer mortality rates are lower in Hispanic women than white women.
Understanding the reasons for such disparities - be it access to care and screening, biological differences in tumors and/or breast cancer subtypes - is the focus of ongoing research efforts across the cancer community, explained Chavez Mac Gregor, the study's first author.
"While these disparities are known, we also understand that breast cancer patients who achieve pathological complete response have better outcomes," said Chavez-Mac Gregor. "What we didn't understand until now was if pathological complete response rates had any relationship with race. If a specific ethnic group had a better or worse response rate, maybe we could then determine which groups may be in need of additional and /or improved therapies."
Using the M. D. Anderson Breast Medical Oncology database, the retrospective study identified 2,074 patients diagnosed with Stages II and III breast cancer and treated at the institution between 1994 and 2008. Of the patients, 1,334 (64.3 percent) were white, 302 (14.6 percent) black, 316 (15.2 percent) Hispanic, and 122 (5.9 percent) were classified as "other" race groups. The median age of the women was 50. All received neoadjuvant anthracycline- and taxane-based chemotherapy; receiving similar class of therapy was an important component in the design of the study, said Chavez Mac Gregor.
At the time of surgery, the researchers found no difference of statistical significance in pCR rates among racial groups: 12.3 percent in whites; 12.5 percent in blacks; 14.24 percent in Hispanics; 11.5 percent in other.
Among all patients, at a median follow-up of 30 months, there were 438 recurrences and 327 deaths. The five year unadjusted recurrence-free (RFS) and overall survival (OS) rates were: 71 percent and 79 percent in whites; 60 percent and 57 percent in blacks; 76 percent and 79 percent in Hispanics; and 75 percent and 84 percent in "other," respectively. Lack of achieving pCR, HER2-positive and triple-negative subtypes, lymph node involvement were all found to be independent predictors of worse RFS and OS.
In further analysis, the study reconfirmed what had been noted in literature - although not statistically significant, blacks tended to have poorer outcomes, while Hispanics had improved outcomes compared to whites, said Chavez Mac Gregor.
The study is not without limitations, she noted: in design, it was both retrospective and a single-institution study, and race was self-reported. In addition, the research focus was until the time of surgery, with less attention towards patients' experience post-surgery, such as compliance to hormone therapies or other adjuvant treatments, other than RFS and OS.
In the same cohort of patients, Chavez Mac Gregor plans further analysis of patients who did not achieve pCR to better understand why they might not have reached this milestone.
University of Texas M. D. Anderson Cancer Center
"Our findings confirm pathological complete response is a strong prognostic indicator and a surrogate for good survival, despite a patient's race, and that it's vital we continue to strive towards achieving this milestone for all women with breast cancer," said Mariana Chavez Mac Gregor, M.D., a medical oncology fellow at M. D. Anderson. "The study also mandates that we continue to research the differences across races in breast cancer."
Racial disparities in breast cancer are known: the American Cancer Society (ACS) estimates that 19,540 blacks and 14,200 Hispanics will be diagnosed with the disease in 2009. While the overall incidence rate is 10 percent lower in blacks than whites, in 2001-2005, they had a 37 percent higher death rate. ACS also reports that overall breast cancer mortality rates are lower in Hispanic women than white women.
Understanding the reasons for such disparities - be it access to care and screening, biological differences in tumors and/or breast cancer subtypes - is the focus of ongoing research efforts across the cancer community, explained Chavez Mac Gregor, the study's first author.
"While these disparities are known, we also understand that breast cancer patients who achieve pathological complete response have better outcomes," said Chavez-Mac Gregor. "What we didn't understand until now was if pathological complete response rates had any relationship with race. If a specific ethnic group had a better or worse response rate, maybe we could then determine which groups may be in need of additional and /or improved therapies."
Using the M. D. Anderson Breast Medical Oncology database, the retrospective study identified 2,074 patients diagnosed with Stages II and III breast cancer and treated at the institution between 1994 and 2008. Of the patients, 1,334 (64.3 percent) were white, 302 (14.6 percent) black, 316 (15.2 percent) Hispanic, and 122 (5.9 percent) were classified as "other" race groups. The median age of the women was 50. All received neoadjuvant anthracycline- and taxane-based chemotherapy; receiving similar class of therapy was an important component in the design of the study, said Chavez Mac Gregor.
At the time of surgery, the researchers found no difference of statistical significance in pCR rates among racial groups: 12.3 percent in whites; 12.5 percent in blacks; 14.24 percent in Hispanics; 11.5 percent in other.
Among all patients, at a median follow-up of 30 months, there were 438 recurrences and 327 deaths. The five year unadjusted recurrence-free (RFS) and overall survival (OS) rates were: 71 percent and 79 percent in whites; 60 percent and 57 percent in blacks; 76 percent and 79 percent in Hispanics; and 75 percent and 84 percent in "other," respectively. Lack of achieving pCR, HER2-positive and triple-negative subtypes, lymph node involvement were all found to be independent predictors of worse RFS and OS.
In further analysis, the study reconfirmed what had been noted in literature - although not statistically significant, blacks tended to have poorer outcomes, while Hispanics had improved outcomes compared to whites, said Chavez Mac Gregor.
The study is not without limitations, she noted: in design, it was both retrospective and a single-institution study, and race was self-reported. In addition, the research focus was until the time of surgery, with less attention towards patients' experience post-surgery, such as compliance to hormone therapies or other adjuvant treatments, other than RFS and OS.
In the same cohort of patients, Chavez Mac Gregor plans further analysis of patients who did not achieve pCR to better understand why they might not have reached this milestone.
University of Texas M. D. Anderson Cancer Center
Breast Cancer Current Events and Breast Cancer News RSSUCLA researchers create 'fly paper' to capture circulating cancer cells
Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.
Fertility procedures need not delay breast cancer treatment for younger women
A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.
Coffee break: Compound brewing new research in colon, breast cancer
A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists.
Drugs to treat anemia in cancer patients linked to thromboembolism
Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.
Discovery in worms by Queen's researchers points to more targeted cancer treatment
Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe
The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated.
Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
Breast density associated with increased risk of cancer recurrence
A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation.
Researcher: 'Optical biopsy' for breast cancer increasingly accurate
But women may not have to endure the medical costs, stress and potential complications that accompany such invasive biopsies forever. A University of Florida biomedical engineering researcher is making progress on an "optical biopsy" that has the potential to determine whether growths are cancerous without ever puncturing the skin.
More Breast Cancer Current Events and Breast Cancer News Articles
 |
New Balance Women's Lace Up X Out Breast Cancer Tech Tee (Athletic Grey, Small) by New Balance The New Balance X Out Breast Caner Tee has a soft hand and clearly states how everyone feels! |
 |
Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer by John Link (Author) A completely updated edition of the definitive guide for patients with breast cancer The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second opinion: why it’s important, what questions to ask, and how to decide which team of doctors is best for you • updates on genetic testing and how doctors are using the results to tailor care for each patient • navigating new types of radiation, the herceptin breakthrough, and improved reconstruction surgeries Conscious of the rapidly evolving spectrum of... |
 |
Sunbeam SlumberRest Camelot Microplush Heated Throw, Breast Cancer Awareness Pink by Sunbeam Soft comfortable fabric that you can cuddle up with anywhere in your house. Use it on the couch while curling up to read a good book or in a chair while watching your favorite show. This throw is 50"x60", with a primstyle control which features 3 warming settings and 3 hour auto-off. So turn on your warming blanket, turn off your thermostat and save on your heating bill. Warm up to a good cause! Sunbeam is joining the fight against breast cancer. Through the purchase of this pink throw, sunbeam will donate $1.00 to city of hope for breast cancer research, treatment and education* up to $25,000. Program ends april 30, 2009. "to save lives and end breast cancer forever by empowering people, ensuring quality care for all, and energizing science to find the cures." *to learn more about... |
 |
1149 WOMENS VINTAGE BLACK ADJUSTABLE FATIGUE CAP w/PINK STRIPES & ''BREAST CANCER'' RIBBON by Rothco A portion of these proceeds go to the Babylon Breast Cancer Coalition- For Life, For Hope, For Change, For the Future Visit www.babylonbreastcancer.org for more information. |
 |
Hope Courage Strength Pink Ribbon Breast Cancer Awareness Expressively Yours Bracelet by MyJewelThief |
 |
Wrangler Women's Tough Enough To Wear Pink Breast Cancer Awareness Jacket,Pink,X-Large by Wrangler Are you tough enough to wear pink? That is the question the western industry asked 12/9/05 at the Wrangler National Finals Rodeo (Wrangler NFR), the "Super Bowl of pro rodeo," as it launched Tough Enough to Wear Pink (TETWP). TETWP is a multi-year, western-industry-wide fundraiser to raise awareness and funds for breast cancer research. TETWP partners are ponying up to support this cause by manufacturing pink merchandise with proceeds benefiting breast cancer research. By wearing this Tough Enough to Wear Pink shirt you are helping in the fight against breast cancer. This TETWP shirt is a pink cotton plaid. Import. Tough Enough to Wear Pink. long sleeve zip front jacket with zippered front slash pockets and the breast cancer embroidery on left chest. 100% Polyester Fleece/100% Nylon... |
 |
Raymond Geddes National Breast Cancer Foundation Pen (67709) by Raymond Geddes Breast Cancer Awareness Pen, Join Geddes in supporting the National Breast Cancer Foundation and the fight against Breast Cancer. Assortment contains pink pens with pink ribbons. Retractable, black in pen ink. 5 1/2" long. |
 |
Just Get Me Through This!: The Practical Guide to Breast Cancer by Deborah A. Cohen (Author), M.D., Robert M. Gelfand (Author) |
 |
Thermos Intak Breast Cancer Awareness 26-Ounce Hydration Bottle by Thermos Nissan Thermos Intak breast cancer awareness hydration bottle is made from bpa free, impact- resistant, dishwasher durable eastman tritan copolyester. The leak-proof lid has an integrated carrying loop. Ideal for water, iced tea, juices and sports drinks: tritan material will not retain flavors or odors of liquid contents. Thermos will donate 3-percent of pink ribbon sales to support breast cancer initiatives. |
 |
Breast Cancer Awareness Ribbon Promise of a Cure Cuff Bracelet by Silver Insanity This Cuff Bracelet Will Fit up to a 8" Wrist and is 3/8" Wide Crafted of a Silver Toned Base Metal and Brought to High Polish Shine Set with a Bright Pink Breast Cancer Awareness Ribbon and Inscribed With The Phrase "Promise of a Cure" |
| © 2009 BrightSurf.com |